Key facts
- Emulate’s last known valuation is $140.0M (Mar 2024).
- It has raised $278.4M across 7 recorded rounds; the latest was Later Stage VC ($57.5M) in Aug 2021.
- Notable investors include Alumni Ventures, Founders Fund, United States Department of War, Qiming Venture Partners, CSC UpShot Ventures — 33 tracked in total.
- Emulate has filed 7 Form Ds with the SEC since 2014, most recently Sep 2021 ($57.5M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 33 names
- ·Watchlist + deal alerts for Emulate
Funding rounds
7 roundsAbout Emulate
Developer of organ-on-a-chip technology designed to predict human response with greater precision and detail than other experimental testing methods. The company's human emulation system provides a window into the inner workings of human biology and disease, offering researchers an innovative technology that conventional cell culture or animal-based experimental testing, enabling doctors to get detailed insights into the human body and its cells.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2013
- Employees
- 76
- Website
- emulatebio.com/
- Ownership
- Privately Held (backing)
Emulate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Emulate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Emulate in its N-PORT filings yet. We sweep new filings monthly.